Nicotinamide (Skin-Cancer Chemoprevention)
Commonly used for
Skin, Hair & Nails
Where to Buy
Our experts personally review each product we recommend for quality and cost effectiveness.
The cheapest product is usually low quality, but more expensive doesn’t always mean better.
The cheapest product is usually low quality, but more expensive doesn’t always mean better.
What is it? / Overview
Nicotinamide is a precursor of NAD+, which restores cellular energy needed for DNA repair after UV exposure and reduces UV-induced immune suppression. A phase 3 randomized trial (ONTRAC) found 500 mg twice daily reduced new non-melanoma skin cancers by 23% over 12 months in immunocompetent adults with a prior history of keratinocyte carcinoma -- one of the strongest RCT evidence bases in this entire database. A separate large trial (ONTRANS) found no benefit in organ-transplant recipients specifically.
How is it used? / Administration
Form: Nicotinamide (niacinamide) oral tablets -- the amide form of vitamin B3; does not cause flushing and does not lower lipids like niacin (nicotinic acid)
Typical dose studied: 500 mg twice daily -- roughly 60x the general-nutrition dose used in the existing Niacin (Vitamin B3) entry
Timing: Twice daily, continuously -- benefit is lost within months of stopping
Distinct from the existing Niacin (Vitamin B3) entry (see that separate entry) -- that entry's chosen form is already niacinamide, but dosed at the general-nutrition RDA level (14-16 mg/day); this entry is the same molecule at a 60x higher dose for a specific, evidence-backed dermatologic indication (prior keratinocyte carcinoma / heavy sun damage history), not general B3 repletion. Keep clearly separate from niacin/nicotinic acid, which does cause flushing and does affect lipids.
How well does it work? / Evidence
✓ Well-established
Who should avoid it?
Avoid with: End-stage liver disease / Cirrhosis; Organ transplant (on immunosuppression)
Already taking it? Well tolerated even at 1,500 mg/day in trials -- reasonable to continue given this is one of the better-evidenced entries in the whole database, but benefit requires continuous use and is not established in organ-transplant recipients specifically, where a separate large trial was negative.
Research & references
Chen AC et al. (2015). A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. New England Journal of Medicine. Allen NC et al. (2023). Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. New England Journal of Medicine. Wehner MR (2025). Keratinocyte Carcinoma. JAMA.
Disclosure: Knozela is a participant in the Amazon Associates affiliate program. Some "Where to buy" links on this page are affiliate links -- if you make a purchase through them, Knozela may earn a commission at no additional cost to you.